ECTRIMS 2023 | The potential role of BTK inhibitors in addressing MS treatment gaps

Erik Wallstroem, MD, PhD, Global Head of Development, Neurology and Opthalmology, Sanofi, and Tom Snow, VP, Global Franchise Head, Neurology and Rare Blood Disorders, Sanofi, discuss the three-year extension results of a trial focused on tolebrutininb for MS treatment. Notably, the safety profile remains consistent and disability progression appears stable, offering reassurance to healthcare professionals. In an open-label trial where patients transitioned from B-cell depletion therapy to BTK inhibitors, a study of the cerebrospinal fluid revealed a reduction in the neurofilament light chain—a marker of axonal damage—after 48 weeks. Although this result is an early indication, the ultimate determination of BTK inhibitors’ potential will be based on Phase III trial data. The findings hint at the possibility of BTK inhibitors addressing MS treatment gaps unmet by current therapies. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.